Cytokinetics, Incorporated

NasdaqGS:CYTK Stock Report

Market Cap: US$3.8b

Cytokinetics Future Growth

Future criteria checks 2/6

Cytokinetics is forecast to grow earnings and revenue by 45.2% and 56.6% per annum respectively. EPS is expected to grow by 46.8% per annum. Return on equity is forecast to be -214.5% in 3 years.

Key information

45.2%

Earnings growth rate

46.8%

EPS growth rate

Biotechs earnings growth24.0%
Revenue growth rate56.6%
Future return on equity-214.5%
Analyst coverage

Good

Last updated08 May 2025

Recent future growth updates

Cytokinetics, Incorporated (NASDAQ:CYTK) Just Reported And Analysts Have Been Cutting Their Estimates

Mar 02
Cytokinetics, Incorporated (NASDAQ:CYTK) Just Reported And Analysts Have Been Cutting Their Estimates

Recent updates

Cytokinetics: Strong Buy As FDA's 3-Month Delay Doesn't Derail Aficamten's Approval Outlook

May 07

Cytokinetics Nears Approval: 'Buy' The New Potential Cardiology Franchise With Aficamten

Mar 16

These Analysts Think Cytokinetics, Incorporated's (NASDAQ:CYTK) Sales Are Under Threat

Mar 05
These Analysts Think Cytokinetics, Incorporated's (NASDAQ:CYTK) Sales Are Under Threat

Cytokinetics, Incorporated (NASDAQ:CYTK) Just Reported And Analysts Have Been Cutting Their Estimates

Mar 02
Cytokinetics, Incorporated (NASDAQ:CYTK) Just Reported And Analysts Have Been Cutting Their Estimates

Cytokinetics Aligns For U.S. Launch Amid HCM Market Evolution

Dec 31

A Look At The Intrinsic Value Of Cytokinetics, Incorporated (NASDAQ:CYTK)

Dec 14
A Look At The Intrinsic Value Of Cytokinetics, Incorporated (NASDAQ:CYTK)

Cytokinetics: On The Cusp Of Commercialization

Nov 14

Cytokinetics: Aficamten Rolling NDA Submission Leads To Expansion Opportunities

Aug 13

Is Cytokinetics (NASDAQ:CYTK) Weighed On By Its Debt Load?

Aug 11
Is Cytokinetics (NASDAQ:CYTK) Weighed On By Its Debt Load?

Cytokinetics' Aficamten: Heartfelt Potential Amid Market Woes

Jul 24

Cytokinetics Decides To Go It Alone

May 24

Here's Why We Think Cytokinetics, Incorporated's (NASDAQ:CYTK) CEO Compensation Looks Fair for the time being

May 09
Here's Why We Think Cytokinetics, Incorporated's (NASDAQ:CYTK) CEO Compensation Looks Fair for the time being

Cytokinetics, Incorporated: Buyout Speculation Persists

Apr 01

Cytokinetics: CEO Talks Down Buyout Prospects

Mar 16

Earnings and Revenue Growth Forecasts

NasdaqGS:CYTK - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2027459-384-449-33515
12/31/2026192-612-573-48418
12/31/202524-664-501-53818
3/31/202519-615-408-398N/A
12/31/202418-590-400-396N/A
9/30/20243-576-407-404N/A
6/30/20243-545-401-399N/A
3/31/20244-531-423-422N/A
12/31/20238-526-416-414N/A
9/30/20238-527-443-438N/A
6/30/202310-540-437-426N/A
3/31/202398-431-406-395N/A
12/31/202295-389-311-300N/A
9/30/2022148-282-272-246N/A
6/30/2022151-216-236-201N/A
3/31/202265-258-183-140N/A
12/31/202170-215-191-143N/A
9/30/202122-229-83-46N/A
6/30/202158-156-178N/A
3/31/202159-135-710N/A
12/31/202056-127-29N/A
9/30/202054-114-68-62N/A
6/30/202019-140-101-97N/A
3/31/202022-132-98-94N/A
12/31/201927-122-94-91N/A
9/30/201931-118-86-84N/A
6/30/201936-110-97-96N/A
3/31/201935-105-99-98N/A
12/31/201832-106N/A-101N/A
9/30/201822-120N/A-113N/A
6/30/201818-131N/A-106N/A
3/31/201814-132N/A-111N/A
12/31/201713-128N/A-102N/A
9/30/201747-80N/A0N/A
6/30/201799-14N/A14N/A
3/31/20171023N/A34N/A
12/31/201610616N/A37N/A
9/30/2016830N/A-51N/A
6/30/201632-42N/A-49N/A
3/31/201633-41N/A-47N/A
12/31/201529-38N/A5N/A
9/30/201541-20N/A7N/A
6/30/201542-17N/A8N/A
3/31/201543-15N/A7N/A
12/31/201447-15N/A-45N/A
9/30/201450-17N/A-49N/A
6/30/201445-23N/A-29N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: CYTK is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CYTK is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CYTK is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CYTK's revenue (56.6% per year) is forecast to grow faster than the US market (8.4% per year).

High Growth Revenue: CYTK's revenue (56.6% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: CYTK is forecast to be unprofitable in 3 years.

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/11 13:23
End of Day Share Price 2025/05/09 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Cytokinetics, Incorporated is covered by 42 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Carter GouldBarclays
Huidong WangBarclays
Jason ZemanskyBofA Global Research